icad inc. Current Part of Debt

Current Part of Debt of ICAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.

Highlights and Quick Summary

  • Current Part of Debt for the quarter ending June 29, 2021 was $851 Thousand (a -23.75% decrease compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt decreased by -53.14%
  • Annual Current Part of Debt for 2020 was $726 Thousand (a -85.5% decrease from previous year)
  • Annual Current Part of Debt for 2019 was $5.01 Million (a 168.38% increase from previous year)
  • Annual Current Part of Debt for 2018 was $1.87 Million (a 125.09% increase from previous year)
Visit stockrow.com/ICAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of icad inc.

Most recent Current Part of Debtof ICAD including historical data for past 10 years.

Interactive Chart of Current Part of Debt of icad inc.

icad inc. Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.85 $1.12
2020 $0.73 $1.82 $0.81 $0.81 $0.73
2019 $5.01 $3.25 $5.01
2018 $1.85 $1.19 $1.87
2017 $0.83
2016 $0.72 $0.09
2014 $5.04 $5.04
2013 $3.88 $3.88

Business Profile of icad inc.

Sector: Healthcare
Industry: Health Information Services
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.